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Anti-cancer agent doxorubicin (DOX) has been demonstrated to worsen insulin signaling,
engender muscle atrophy, trigger pro-inflammation, and induce a shift to anaerobic
glycolytic metabolism in skeletal muscle. The myotoxicity of DOX in diabetic skeletal
muscle remains largely unclear. This study examined the effects of DOX on insulin
signaling, muscle atrophy, pro-/anti-inflammatory microenvironment, and glycolysis
metabolic regulation in skeletal muscle of db/db diabetic and db/+ non-diabetic mice.
Non-diabetic db/+ mice and diabetic db/db mice were randomly assigned to the
following groups: db/+CON, db/+DOX, db/dbCON, and db/dbDOX. Mice in db/+DOX
and db/dbDOX groups were intraperitoneally injected with DOX at a dose of 15mg per
kg body weight whereas mice in db/+CON and db/dbCON groups were injected with
the same volume of saline instead of DOX. Gastrocnemius was immediately harvested,
weighed, washed with cold phosphate buffered saline, frozen in liquid nitrogen, and
stored at −80◦C for later analysis. The effects of DOX on diabetic muscle were
neither seen in insulin signaling markers (Glut4, pIRS1Ser636/639, and pAktSer473) nor
muscle atrophy markers (muscle mass, MuRF1 and MAFbx). However, DOX exposure
resulted in enhancement of pro-inflammatory favoring microenvironment (as indicated by
TNF-α, HIFα and pNFκBp65) accompanied by diminution of anti-inflammatory favoring
microenvironment (as indicated by IL15, PGC1α and pAMPKβ1Ser108). Metabolism of
diabetic muscle was shifted to anaerobic glycolysis after DOX exposure as demonstrated
by our analyses of PDK4, LDH and pACCSer79. Our results demonstrated that there
might be a link between inflammatory modulation and the dysregulation of aerobic
glycolytic metabolism in DOX-injured diabetic skeletal muscle. These findings help to
understand the pathogenesis of DOX-induced myotoxicity in diabetic muscle.
Keywords: type 2 diabetes mellitus, cancer chemotherapy, myotoxicity, anaerobic glycolysis, pro-inflammation,
anti-inflammation
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INTRODUCTION
Doxorubicin (DOX) is an effective chemotherapeutic drug for
treating various types of cancer (Cortés-Funes and Coronado,
2007; Tacar et al., 2013). Nonetheless, the side effects of DOX on
cardiomyocytes leading to life-threatening cardiomyopathy have
limited its clinical use (Swain et al., 2003). Indeed, the adverse side
effects of DOX have also been documented in the brain (Aluise
et al., 2010), liver (Gokcimen et al., 2007), kidney (Wapstra
et al., 1999), lung (Lim et al., 2010), blood vessels (Murata et al.,
2001), and skeletal muscle (Smuder et al., 2011; Hayward et al.,
2013). DOX is a potent drug for chemotherapy and it reflects
a common picture of the chemotherapeutic drugs used for
treating cancer (Shaikh and Shih, 2012). Generation of reactive
oxygen species (ROS) and apoptosis-inducing characteristics are
the common features shared by the anticancer drugs (Minotti
et al., 2004; Nitiss, 2009; Gilliam and St. Clair, 2011). DOX
has been demonstrated to adversely affect the muscle quality
and muscle mass (Falkenberg et al., 2001; Gilliam and St. Clair,
2011; Smuder et al., 2011). DOX treatment was demonstrated
to increase calcium flux from isolated sarcoplasmic reticulum
vesicles in skeletal muscle cells (vanNorren et al., 2009). DOX has
also been shown to reduce calcium sensitivity by interfering with
actin-myosin interaction in skeletal muscle (Hydock et al., 2011).
Other adverse physiological consequences of DOX in skeletal
muscle include muscle atrophy, muscle cell death, muscle mass
reduction, and decrease in maximal twitch force (Falkenberg
et al., 2001; Arthur et al., 2008; Gilliam and St. Clair, 2011;
Smuder et al., 2011). DOX is comprised of a quinone moiety in
its chemical structure, which is responsible for causing oxidative
stress by interacting with molecular oxygen in skeletal muscle
fibers (Chen et al., 2007). The resultant elevated oxidative
stress disrupts several cellular mechanisms involving calpain and
caspase-3 protease (Gilliam and St. Clair, 2011), AMP-activated
protein kinase (AMPK) (Irrcher et al., 2008), and insulin receptor
substrate 1 (IRS1) (Martins et al., 2012), in which DOX impairs
the processes of apoptosis, autophagy, insulin signaling, and
inflammatory pathways.
Inflammation and dysregulated glycolytic metabolism are
reported in type 2 diabetes mellitus (Simoneau and Kelley,
1997; Pickup, 2004). Oxidative stress, inflammatory modulation
and dysregulated glycolytic metabolism have also been reported
in the DOX-exposed skeletal muscle ( van Etten et al., 1998;
Hardin et al., 2008; van Norren et al., 2009). Diabetes in
skeletal muscle weakens the tricarboxylic acid (TCA) cycle
(Ritov et al., 2010) and releases enormous amount of ROS
by downregulating peroxisome proliferator-activated receptor
gamma coactivator 1-alpha (PGC1α) (Mootha et al., 2003;
Sparks et al., 2005), which is one of the important mediators
in the DOX-induced skeletal muscle myopathy (Min et al.,
2015). ROS-PGC1α signaling is a key pathway in the regulation
of mitochondrial function in skeletal muscle and they are
inversely related to each other (Liao, 2012). The augmented
oxidative stress induced by DOX in diabetic skeletal muscle
might cause metabolic dysregulation by inhibiting oxidative
phosphorylation and upregulating lactate dehydrogenase (LDH)
(Tannahill et al., 2013). The upregulated LDH leads to the
activation of hypoxia-induced factor 1α (HIF1α) (Tannahill et al.,
2013) and nuclear factor kappa B (NFκB) (Remels et al., 2014),
which are transcription factors and regulatory molecules that
favor toward pro-inflammatory microenvironment and trigger
the secretion of pro-inflammatory cytokines [e.g., tumor necrosis
factor alpha (TNFα) (Hotamisligil and Spiegelman, 1994) and
Interleukin 6 (IL6) (Franckhauser et al., 2008)]. On the other
hand, DOX has also been demonstrated to induce oxidative
stress in skeletal muscle without altering LDH (van Norren
et al., 2009) but to cause insulin resistance in muscle by
downregulating IRS-1, glucose transporter type 4 (GLUT4),
AMPK and glycogen synthase kinase 3 beta (GSK3β) (Hayward
et al., 2013). While AMPK downregulation is suggested to be
involved in insulin resistance development in skeletal muscle
treated with DOX (Viollet et al., 2009), AMPK also acts as
a metabolic master switch that phosphorylates target proteins
in fatty acid oxidation metabolic pathways in skeletal muscle
(Viollet et al., 2009). Besides, AMPK acts as a regulatory
molecule favoring the anti-inflammatory microenvironment
leading to the shift toward oxidative metabolism (Sag et al.,
2008), which reduces glycolytic rate by activating PGC1α that
ameliorates inflammatory cytokines/myokines such as TNFα and
IL6 (Ostrowski et al., 1999; Steinberg et al., 2006) and enhances
anti-inflammatory cytokines/myokines such as IL15 and IL10
(Wang et al., 2014; Crane et al., 2015).
Approximately 8–18% of patients with cancer are diabetic
(Richardson and Pollack, 2005). Also, patients with diabetes
are at a higher risk of developing cancers in breast, pancreatic,
liver, kidney, endometrial, and colon (Richardson and Pollack,
2005). Though the exact links between diabetes and cancer are
not known, the exposure to hyperglycemia, elevated insulin,
and growth-promoting IGF-1 have been postulated to be the
possible reasons explaining the increased incidence of cancers
in diabetic patients (Grimberg, 2003). Nevertheless, patients
with diabetes and cancer need to be particularly considered for
undergoing chemotherapy due to the detrimental side effects
of the chemotherapeutic drugs (Psarakis, 2006). In regard to
DOX myotoxicity, DOX has been demonstrated to worsen
insulin signaling, engender muscle atrophy, disseminate pro-
inflammation, and induce an oxidative-to-glycolytic metabolic
shift in normal skeletal muscle (Braun et al., 2014; Fabris and
MacLean, 2015; de Lima Junior et al., 2016). However, the effects
of DOX on skeletal muscle of diabetic individuals are largely
unclear and the responsible molecular mechanisms in diabetic
muscle remain to be elucidated. This study aimed to examine
the effects of DOX on insulin signaling, muscle atrophy, pro-
/anti-inflammatory microenvironment, and glycolysis metabolic
regulation in skeletal muscle of diabetic animals.
METHODS
Animal
Male 14- to 18-week-old db/db mice were obtained from the
Laboratory Animal Services Centre of The Chinese University
of Hong Kong. The db/db mouse is a well-established leptin
receptor-deficient animal model (homozygous allelic deficient
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for the leptin receptor gene) that mimics the disease phenotype
of human type 2 diabetes mellitus. Non-diabetic db/+ mice
(heterozygous allele deficient for the leptin receptor gene) of the
same genetic background as db/db mice were used as control
group. Mice were housed in a humidity- and temperature-
controlled environment and were exposed to a 12:12-h light:dark
cycle in the Centralized Animal Facilities of The Hong Kong
Polytechnic University. Mice were allowed to have access to
standard animal diet and water ad libitum. Animal ethics
approval was obtained from the Animal Ethics Sub-committee
of The Hong Kong Polytechnic University.
Experimental Protocol
Non-diabetic db/+mice and diabetic db/db mice were randomly
assigned to the following groups: db/+CON, db/+DOX,
db/dbCON, and db/dbDOX (n = 5 per group). The diabetic
status of our examined db/db mice was confirmed by the
measurements of fasting blood glucose level (db/dbmice vs. db/+
mice: 27.1 ± 1.0 mmol/L vs. 7.8 ± 0.5 mmol/L) and HbA1c
level (db/db mice vs. db/+ mice: 7.0 ± 0.4% vs. 5.8 ± 0.1%).
Mice in db/+DOX and db/dbDOX groups were intraperitoneally
injected at one time point with DOX (Pharmacia and Upjohn
SpA, Milan, Italy) at a dose of 15mg per kg body weight whereas
mice in db/+CON and db/dbCON groups were injected with
the same volume of saline instead of DOX (Yu et al., 2014;
Pei et al., 2015). Five days after the DOX administration, the
gastrocnemius was immediately harvested, weighed, washed with
cold phosphate buffered saline (PBS), frozen in liquid nitrogen,
and stored at−80◦C for later analysis (Yu et al., 2014).
Protein Fraction Preparation
Protein fractions were extracted from muscle homogenates as
previously described (Yu et al., 2014; Pei et al., 2015) Forty
mg of sample tissue were minced and homogenized in ice-cold
lysis buffer (10mmol/L NaCl, 1.5mmol/L MgCl2, 20 mmol/L
HEPES, pH 7.40, 20% glycerol, 0.1% Triton X-100, and 1 mM
dithiothreitol). Homogenates were subject to centrifugation at
875 × g for 5min at 4◦C. The supernatant was obtained and
subject to further centrifugation at 3500 × g for 5min at 4◦C
in which these procedures were repeated thrice. Finally, the
supernatant was collected as the cytoplasmic protein fraction.
Then, protease inhibitor cocktail (P8340, Sigma-Aldrich) was
added to the cytoplasmic protein fraction. Protein concentration
was quantified in triplicates by Bradford assay (Coomassie
Protein Assay, Pierce) with bovine serum albumin used as the
standard.
Western Blot Analysis
The protein abundances of insulin signaling markers (IRS-
1Ser636/639, AktSer473, GLUT4), muscle atrophy markers
(MuRF1 and MAFbx), markers for pro-inflammatory favoring
microenvironment (TNFα, IL6, HIF1α, pNFkBp65), markers
for anti-inflammatory favoring microenvironment (IL10, IL15,
pAMPKβ1Ser108, PGC1α) and metabolic regulators (PDK4,
pACCSer79, LDH) were evaluated by Western blotting. Forty
micrograms of protein were denatured at 95◦C for 5 min
in Laemmli buffer with 5% β-mercaptoethanol. The protein
samples were subject to gel electrophoresis on 10% SDS-PAGE
gel. Resolved proteins were then transferred to polyvinylidene
difluoride (PVDF) membranes (Immobilon-P, Millipore) by
using the Bio-Rad Mini-Protein II system. The membrane
was then blocked with 5% skimmed milk powder in PBS/0.1%
Tween-20 (PBST) followed by incubation with respective
primary antibodies overnight at 4◦C. The primary anti-bodies
used for probing various markers, their sources and dilutions
used are listed in the Table 1. Membranes were incubated with
appropriate secondary antibodies (i.e., anti-mouse, anti-rabbit
or anti-goat IgG horseradish peroxidase-conjugated antibodies;
Cell Signaling, 1:4000) after washing. The immunoreactivity
was determined using the ECL chemiluminescence reaction
kit (Perkin Elmer) and the images were captured by Chemi
Doc (Bio-Rad camera, USA). GAPDH was used as the internal
loading control. The arbitrary units of the blot signal are
presented as net intensity x band area, normalized to the signal
of GAPDH or the respective total protein for phosphorylation
status.
Lactate Dehydrogenase (LDH) Activity
Lactate dehydrogenase (LDH) activity was determined by a
commercially available kit (ab102526, Lactate Dehydrogenase
Activity Colorimetric Assay Kit, Abcam). The assay was
performed according to the manufacturer’s instruction. In brief,
LDH converts pyruvate into lactate that reduces the developer
to a colored product with absorbance at 450 nm measured by a
microplate reader (Infinite F200, Tecan, Switzerland).
TABLE 1 | List of antibodies used.
Antibody Dilution
factor
Source
Anti-phospho-IRS1 (Ser636/639)
rabbit polyclonal
1:1000 2388, Cell signaling technology
Anti-phospho-Akt (Ser473) rabbit
polyclonal
1:1000 9271, Cell signaling technology
Anti-Akt rabbit polyclonal 1:1000 9272, Cell signaling technology
Anti GLUT4 rabbit polyclonal 1:500 07-1404, Millipore
Anti-MuRF1 rabbit polyclonal 1:500 32920, Santa Cruz
Anti-MAFbx rabbit polyclonal 1:500 33782, Santa Cruz
Anti-phospho-AMPKβ1(Ser108)
rabbit polyclonal
1:1000 4181, Cell signaling technology
Anti PGC1α rabbit polyclonal 1:500 13067, Santa Cruz
Anti-IL10 goat polyclonal 1:1000 365858, Santa Cruz
Anti-IL15 goat polyclonal 1:1000 1296, Santa Cruz
Anti-phospho-NFkβ p65 rabbit
monoclonal
1:1000 3033, Cell signaling technology
Anti-HIF1α rabbit polyclonal 1:500 10790, Santa Cruz
Anti-TNFα goat polyclonal 1:1000 52746, Santa Cruz
Anti-IL6 goat polyclonal 1:1000 1265, Santa Cruz
Anti-PDK4 (Thr410/403) goat
polyclonal
1:1000 14495, Santa Cruz
Anti-phospho-ACC (Ser79) rabbit
polyclonal
1:1000 3661, Cell signaling technology
Anti-LDH rabbit polyclonal 1:500 33781, Santa Cruz
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Data Analyses
Statistical analyses were performed by using the SPSS 21.0
software package (IBM, Chicago, IL, USA). Normality tests were
performed to examine data distribution. All data were expressed
as mean± standard error of the mean (SEM). Two-way ANOVA
was used to examine the interaction and main effects of the two
experimental factors (i.e., diabetes and DOX) and subsequent
Tukey’s HSD post-hoc test was used to examine the simple effect
if a significant interaction effect was found. Statistical significance
was set at p < 0.05. Of note, the adopted sample size in the
present study resulted in a statistical power of 80% or above for
the assessments including muscle mass, IRS1, MAFbx, IL6, IL10,
IL15, AMPK, PGC1α, HIF1α, and LDH activity.
RESULTS
No Exacerbating Effect of DOX Exposure
on Insulin Signaling in Diabetic Muscle
The abundance of insulin signaling proteins including phosphor-
IRS1Ser636/639, phosphor-AKTSer473 andGLUT4weremeasured
in the gastrocnemius muscle. No interaction effect of diabetes
and DOX was observed in all the three markers. We observed the
main effect of diabetes for phosphor-IRS-1 (P = 0.0001) and the
abundance of protein was significantly increased by 145% (P =
0.0001) in the gastrocnemius muscle of db/dbCON mice relative
to that of db/+CONmice (Figure 1A). There was a main effect of
diabetes for AKT (P= 0.042), and the protein abundance of AKT
was significantly reduced by 61% (P = 0.041) in the muscle of
db/dbCONmice relative to db/+CONmice (Figure 1B). We did
not observe interaction effect of diabetes with DOX or significant
main effect of diabetes in GLUT4 (Figure 1C).
No Exacerbating Effect of DOX Exposure
on Muscle Atrophy in Diabetic Muscle
The abundance of muscle atrophy markers including MuRF1,
MAFbx and muscle mass were measured in the gastrocnemius
muscle. No interaction effect of diabetes with DOX was found
for MuRF1. There was a significant main effect of diabetes
for MuRF1 (P = 0.022) and a significant 48.28% (P = 0.022)
increase in protein abundance ofMuRF1 inmuscle of db/dbCON
mice relative to that of db/+CON mice (Figure 2A). We did
not observe any significant interaction effect for MAFbx. Also,
no significant main effect of diabetes was found in MAFbx
(Figure 2B). No significant interaction effect was observed in the
muscle mass. However, significant main effect of diabetes was
observed in muscle mass reduction (P = 0.0001) and muscle
mass was significantly decreased by 58% (P = 0.0001) in the
gastrocnemius muscle of db/dbCON mice relative to that of
db/+CONmice (Figure 2C).
DOX Caused Anti-Inflammatory
Microenvironment Diminution and
Pro-Inflammatory Microenvironment
Augmentation in Diabetic Muscle
The muscle-specific cytokines, transcription factor and
regulatory molecule that modulate anti-inflammatory
microenvironment were examined. No interaction effect of
diabetes with DOX was observed for IL10. Significant main
effect of diabetes was observed in IL10 (P = 0.001) and its
protein abundance significantly decreased by 78% (P = 0.001)
in the muscle of db/dbCON mice relative to that of db/+CON
mice (Figure 3A). No interaction effect of diabetes with DOX
was observed for IL15. Significant main effect of diabetes was
found in IL15 (P = 0.001). The protein abundance of IL15
was significantly decreased by 51% (P = 0.001) in muscle of
db/dbDOX mice relative to the muscle of db/+DOX mice and it
was also significantly decreased by 66% (P= 0.043) in the muscle
of db/dbDOX mice relative to db/dbCON mice (Figure 3B).
Similarly, no interaction effect of diabetes and DOX was
observed in AMPK. Significant main effect of diabetes was found
in AMPK (P= 0.0001). There was a significant 62% (P= 0.0001)
decrease in protein abundance of phosphor AMPKβ1Ser108 in
muscle of db/dbCON mice relative to db/+CON mice and was
also significantly decreased by 57% (P = 0.004) in db/dbDOX
mice relative to that of db/dbCON mice (Figure 3C). Significant
interaction effect of diabetes with DOX (P = 0.039) for PGC-1α
was found. A significant 31% (P = 0.001) decrease in protein
abundance of PGC-1α in the muscle of db/dbCON relative to
the muscle of db/+CON mice and also a significant 36% (P =
0.031) decrease in the muscle of db/dbDOX relative to that of
db/dbCONmice was observed (Figure 3D).
The muscle-specific cytokines, transcription factor and
regulatory molecule that modulate pro-inflammatory favoring
microenvironment were assessed. No interaction effect of
diabetes with DOX was observed for IL6. Significant main
effect of diabetes was found in IL6 (P = 0.006). The protein
abundance of IL6 was significantly increased by 37% (P = 0.003)
in muscle of db/dbCON mice relative to that of db/+CON mice
(Figure 4A). Significant interaction effect of diabetes and DOX
was observed for TNFα (P = 0.038). The protein abundance
of TNFα was increased by 35% (P = 0.0001) in muscle of
db/dbDOX mice relative to that of db/+DOX. TNFα was also
increased by 13% (P = 0.036) in the muscle of db/dbDOX
mice relative to db/dbCON mice (Figure 4B). No interaction
effect of diabetes and DOX was observed for NFkB. Significant
main effect of diabetes was observed for NFkB (P = 0.001).
There was a significant 47% (P = 0.001) increase in phosphor-
NFkB in db/dbDOX muscle relative to db/+DOX muscle and
a significant 46% (P = 0.0023) increase in phosphor-NFkB in
db/dbDOX muscle relative to db/dbCON muscle (Figure 4C).
Significant interaction effect of diabetes with DOX was observed
in HIF-1α (P = 0.05). The protein abundance of HIF-1α was
increased by 635% (P = 0.0001) in muscle of db/dbDOX mice
relative to db/+DOX mice. HIF-1α and increased by 47% (P
= 0.05) in db/dbDOX mice relative to that of db/dbCON mice
(Figure 4D).
DOX Caused a Shift toward Anaerobic
Glycolysis in Diabetic Muscle
Anaerobic glycolysis favoring metabolic regulators including
pyruvate dehydrogenase lipoamide kinase isozyme 4 (PDK4),
ACC, and LDH were examined. Significant interaction effect
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FIGURE 1 | Non-diabetic and diabetic skeletal muscle insulin signaling after DOX exposure examined by phosphorylation statuses of
IRS1(Ser636/639) (A), Akt (Ser473) (B), and GLUT4 (C) are shown. Data are expressed as mean ± SEM.
of diabetes with DOX was observed in PDK4 (P = 0.019).
The protein abundance of PDK4 significantly increased by 94%
(P = 0.03) in the muscle of db/dbDOX mice relative to the
muscle of db/+DOX mice and significantly increased by 34%
(P = 0.05) in the muscle of db/dbDOX mice relative to that
of db/dbCON mice (Figure 5A). Significant interaction effect
of diabetes with DOX was observed in ACC (P = 0.007).
There was a significant 12% (P = 0.045) decrease in protein
abundance of phosphor-ACC in the muscle of db/dbCON
relative to that of db/+CON mice. Muscle of db/dbDOX mice
showed a significant 68% (P = 0.02) decrease in protein
abundance of phosphor-ACC relative to that of db/dbCON
mice (Figure 5B). Significant interaction effect of diabetes and
DOX was observed for both LDH protein abundance (P =
0.0001) and LDH activity (P = 0.047). There was a significant
47% (P = 0.0001) increase in the protein abundance of LDH
in the muscle of db/dbDOX mice relative to db/+DOX mice
and a 31% (P = 0.01) increase in LDH in the muscle of
db/dbDOX mice relative to that of db/dbCON (Figure 5C). A
significant 134% (P = 0.001) increase in LDH activity in muscle
of db/dbDOX mice relative to that of db/+DOX mice was found
(Figure 5D).
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FIGURE 2 | Non-diabetic and diabetic skeletal muscle atrophy after DOX exposure examined by phosphorylation statuses of MuRF1 (A) and MAFbx
(B) muscle mass (mg) (C) are shown. Data are expressed as mean ± SEM.
DISCUSSION
In this study, we demonstrated that DOX treatment in diabetic
skeletal muscle did not exacerbate the impairment of insulin
signaling and muscle atrophy as compared to non-diabetic
skeletal muscle. However, DOX augmented pro-inflammatory
microenvironment in diabetic muscle by upregulating
transcription factor HIF1α, regulatory molecule pNFκBp65,
and cytokine TNFα. DOX also altered anti-inflammatory
microenvironment by downregulating transcription
factor PGC1α, regulatory molecule pAMPKβ1Ser108 and
muscle-specific myokine IL15. In addition, DOX induced
dysregulated glycolytic metabolism in diabetic skeletal muscle
by upregulating PDK4 and LDH and downregulating
phosphorylation of acetyl-CoA carboxylase (pACC
Ser79).
Type 2 diabetes (T2D) is a progressive chronic disease,
primarily characterized by functional decline of beta cell,
worsening of insulin signaling, and muscle atrophy (Trostler
et al., 1982; Cotter et al., 1993; Fonseca, 2009; Brannmark et al.,
2013; de Lima Junior et al., 2016). DOX administration in
non-diabetic skeletal muscle has been shown to cause insulin
resistance and degradation of muscle quality (Hydock et al.,
2011; Smuder et al., 2011; de Lima Junior et al., 2016). In
the present study, our results are consistent with the previous
findings of insulin signaling and muscle atrophy markers in
diabetic muscle and DOX-treated muscle. However, our data
indicated that there was no significant difference in insulin
signaling and muscle atrophy markers in DOX-treated diabetic
skeletal muscles when compared to diabetic skeletal muscles
without DOX exposure. We interpreted that, in diabetic skeletal
muscle, the diabetic characteristics (i.e., insulin signaling and
muscle atrophy) were already worsened and hence the DOX
exposure did not lead to a further impairment of insulin signaling
and muscle atrophy markers. We did not observe significant
difference in anti-inflammatory microenvironment (IL10, IL15,
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FIGURE 3 | Non-diabetic and diabetic skeletal muscle anti-inflammatory microenvironment after DOX exposure examined by phosphorylation of
myokines: IL10 (A), IL15 (B) AMPKβ1Ser108 (key regulator) (C) and PGC1α (transcription factor) (D) are shown. Data are expressed as mean ± SEM.
AMPK, and PGC1α), pro-inflammatory microenvironment (IL
6, TNF α, NFkB, and HIF1α) as well as in metabolic regulators
(ACC, PDK4, and LDH) in skeletal muscles treated with DOX
when compared to skeletal muscle without DOX exposure. We
inferred that, DOX exposure may primarily affect the insulin
sensitivity (de Lima Junior et al., 2016) and muscle atrophy
(Chen et al., 2007) due to the accumulation of reactive oxygen
species in the skeletal muscle (van Etten et al., 1998; Hardin
et al., 2008; van Norren et al., 2009), and this is affected
by the modulation of inflammatory microenvironment and
metabolic dysregulation in the plasma (Haus et al., 2009).
Nevertheless, our results suggested that DOX administration in
diabetic skeletal muscle might cause an environment which is
favorable toward aggregating pathogenesis of T2D as indicated
by our observations of the inflammatory upsurge and metabolic
dysregulation (Rhodes, 2005; Fonseca, 2009; Rocha et al.,
2016).
The Link of Diminution of
Anti-Inflammatory Microenvironment and
Dysregulated Oxidative Metabolism
AMPK, a regulatory molecule favoring anti-inflammatory
microenvironment (O’Neill and Hardie, 2013), directly activates
PGC1α (Jäger et al., 2007) and regulates IL15 (Crane et al.,
2015). Therefore, downregulation of AMPK in diabetic skeletal
muscles after DOX treatment leading to the reduction of
PGC1α and IL15 might indicate the diminution of the anti-
inflammatorymicroenvironment, as shown in our results. AMPK
activation in skeletal muscle has been shown to result in muscle
fiber shifting from glycolytic fibers to oxidative fibers in a
PGC1α-dependent manner (Garcia-Roves et al., 2008). AMPK
was also demonstrated to stimulate fatty acid oxidation and
reduce the activity of acetyl-coenzyme A (CoA) carboxylase,
which is an enzyme carrying out the conversion of acetyl CoA
to malonyl CoA (Castle et al., 2009) that directs fatty acid
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FIGURE 4 | Non-diabetic and diabetic skeletal muscle pro-inflammatory microenvironment after DOX exposure examined by phosphorylation
statuses of myokines: IL6 (A) TNFα (B) pNFkBp65 (Key regulator) (C) and HIF1α (transcription factor) (D) are shown. Data are expressed as mean ± SEM.
oxidation in skeletal muscle (Abu-Elheiga et al., 2001). Since
the phosphorylation of ACC was significantly downregulated
in our examined muscles, we suspected that DOX decreased
fatty acid oxidative metabolism in diabetic skeletal muscle. It
has been reported that oxidative phosphorylation (OXPHOS)
genes are strongly correlated to PGC1α in diabetic skeletal
muscle based on DNA microarray analysis (Mootha et al., 2003);
also, it has been reported that DOX treatment in the heart
inhibited oxidative phosphorylation (Abdel-aleem et al., 1997)
and reduced phosphorylation of ACC in white adipose tissue
(Biondo et al., 2016). Consistently, we demonstrated in our
examined muscle, the decreases in AMPK and PGC1α, which
induced glycolytic shift as indicated by the downregulation
of pACCSer79. Overall, our findings suggest that there might
be a link between anti-inflammatory microenvironment and
dysregulated metabolism in the DOX-induced myotoxicity in
diabetic skeletal muscle. Further research is needed to fully
dissect the regulatory mechanisms of the link the inflammatory
microenvironment and metabolism dysregulation in DOX-
injured diabetic skeletal muscle.
The Link of Augmentation of
Pro-Inflammatory Microenvironment and
Anaerobic Glycolytic Metabolism
NFκB, a regulatory molecule favoring pro-inflammatory
microenvironment (Eisele et al., 2013) has been shown to
be activated by ROS (Dodd et al., 2010) and TNFα (Remels
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FIGURE 5 | Non-diabetic and diabetic skeletal muscle glycolytic mechanism after DOX exposure examined by phosphorylation statuses of PDK4 (A)
and ACC (Ser79) (B) LDH protein (C) LDH activity (D) are shown. Data are expressed as mean ± SEM.
et al., 2014) in skeletal muscle. Additionally, classical activation
of NFκB was demonstrated to augment muscle glycolytic
metabolism in a HIF1α-dependent manner (Remels et al.,
2014). Our results exhibited that the upregulation of TNFα
activated NFκB and augmented glycolytic metabolism in
HIF1α-dependent manner. Notably, DOX has been reported
to induce cardiotoxicity by decreasing conversion of acetyl-
CoA to malonyl CoA and the decreased rate of conversion
inhibited fatty acid oxidation and ATP generation (Peluso
et al., 2000). Consistently, an anti-diabetic drug (metformin)
has been shown to prevent cardiotoxicity induced by DOX
by increasing fatty acid oxidation and preventing energy
starvation (Ashour et al., 2012). Metformin in combination
with DOX has been demonstrated to inhibit the inflammatory
pathway by inhibiting NFκB (a pro-inflammatory regulatory
molecule) in mammalian cancer cell line (Hirsch et al., 2013).
We suspected that if metformin suppressed the effect of
DOX toxicity by enhancing phosphorylation of ACC and
decreasing NFκB, then DOX induction along with diabetes
might reduce ACC phosphorylation and aggravate inflammation
by triggering NFκB according to the present findings. Since
NFκB augmented muscle glycolytic metabolism in a HIF1α-
dependent manner (Remels et al., 2014), HIF1α upregulation
might be an indicator of an increase in glycolytic metabolism,
as shown in our data. Our observed increase in TNFα suggested
that NFκB was increased in a PGC1α-dependent fashion as
it has been demonstrated that TNFα increased NFκB binding
to PGC1α, which downregulated PGC1α and subsequently
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FIGURE 6 | DOX administration in diabetic skeletal muscle leads to upsurge of pro-inflammatory microenvironment (HIF1α, NFκB, TNFα) along with
upsurge of anaerobic glycolytic metabolic regulators (PDK4, LDH) and diminution of anti-inflammatory microenvironment (PGC1α, AMPK, IL15) along
with diminution of aerobic metabolic regulator (pACCSer108).
dysregulated glucose metabolism (Lvarez-Guardia et al.,
2010).
The Upsurge of Anaerobic Glycolytic
Metabolism
Diabetes causes muscle energy starvation (Simoneau and Kelley,
1997) and DOX causes muscle fatigue (van Norren et al.,
2009); hence, it is proposed that when DOX is administered
in diabetic skeletal muscle, pro-inflammatory microenvironment
upsurge might take place to undergo profound metabolic
changes to mediate metabolic adaptation caused by DOX
in diabetic skeletal muscle. It has been shown that HIF1α
(pro-inflammatory transcription factor) led to upregulation of
anaerobic glycolysis and release of lactate (Tannahill et al.,
2013). Glycolysis is the metabolic pathway that converts glucose
to pyruvate aerobically and lactate anaerobically (Scott, 2008).
Interconversion of pyruvate to lactate and vice versa is carried
out by LDHduring intensive exercise (Spriet, 1995). Consistently,
we observed increases in HIF1α and LDH in our examined
muscles and it might be possible that the upsurge of pro-
inflammatory regulatory molecule has stabilized HIF1α, which
led to lactate release posing an aerobic-to-anaerobic metabolic
shift. Our interpretation is supported by a study reporting
that diabetic skeletal muscle has increased glycolytic rate with
upregulation of LDH (Tannahill et al., 2013). The increase in
pyruvate dehydrogenase lipoamide kinase isozyme 4 (PDK4)
indicated the accumulation of fatty acid, which has been
demonstrated to be upregulated in diabetic skeletal muscle (Rosa
et al., 2003) and in DOX-treated skeletal muscle (Sin et al.,
2015). Nonetheless, HIF1α (pro-inflammatory transcription
factor) might also have induced the alteration of PDK4
(Meiser et al., 2016), which was consistent with our findings.
Collectively, our results demonstrated that DOX increased the
abundances of PDK4, LDH and HIF1α with the downregulation
of ACC phosphorylation, and established a pro-inflammatory
environment in diabetic skeletal muscle in a HIF1α-dependent
manner.
DOX and diabetes individually have been demonstrated to
cause the release of ROS that might lead to muscle fatigue
and metabolic dysregulation (van Etten et al., 1998; Hardin
et al., 2008; van Norren et al., 2009; Ritov et al., 2010),
which are in accordance with our present findings of muscle
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atrophy and insulin signaling markers. Hence, we speculated
that DOX in diabetic skeletal muscle might have induced further
elevation of ROS production when compared to DOX or diabetes
alone. Excessive ROS production has been shown to increase
the inflammatory response (Barreiro et al., 2005; Fruehauf
and Meyskens, 2007; Zuo et al., 2013a,b) and dysregulate
multiple regulatory enzymes such as glutathione peroxidase
(GPx), superoxide dismutase (SOD), and catalase (Zuo et al.,
2015). In DOX-treated diabetic skeletal muscle, we observed the
upregulation of pro-inflammatory microenvironment regulatory
molecule (NFkB) and cytokines (TNFα) that might be due to
the over-production of ROS (Wang et al., 2011). The balance
of ROS has been shown to play an important role in the
adaptation and response of the glycolytic activity (Blair et al.,
1999). In the present study, the observations on the increase
in LDH and PDK4 along with the decrease in ACC leading to
dysregulated metabolism suggest that there might be excessive
ROS production in DOX-treated diabetic skeletal muscle. High
level of glucose or fatty acids is known to enhance ROS
production, which plays a vital role in the loss of the number or
function of pancreatic beta cells. On the contrary, ROS have been
reported to be produced under high or low glucose concentration
in pancreatic beta cells by activating AMPK in a superoxide-
dependent manner (Sarre et al., 2012). In our results, we found
that AMPK was downregulated suggesting that high level of
glucose might have resulted in the over-production of ROS in
the DOX-treated diabetic skeletal muscle. As ROS play a critical
role in inflammation, calcium flux, muscle death and atrophy,
diabetes and aerobic metabolism, additional investigation is
warranted to comprehensively examine the role of ROS in the
modulations of inflammation and metabolism in DOX-treated
diabetic muscle.
In conclusion, our data demonstrated that the modulation
of the inflammatory pathway might be linked to the shift of
oxidative-glycolytic metabolism in diabetic skeletal muscle after
DOX exposure (Figure 6). Our findings that the increases in
pro-inflammatory transcription factor HIF1α and regulatory
molecule NFκB along with the augmentation of inflammatory
cytokine TNFα in DOX-injured diabetic muscle might help
to reveal the underlying mechanisms and thus hasten the
development of new effective strategies to protect skeletal
muscle from DOX-induced toxicity in diabetic cancer patients.
Moreover, the present findings of the decreases in transcription
factor PGC1α and regulatory molecule AMPK along with the
diminution of anti-inflammatory myokine IL15 in DOX-injured
diabetic muscle might indicate inverse relationship with anti-
inflammatory microenvironment and glycolytic metabolism.
Although the adopted sample size has resulted in a statistical
power of 80% or above for the assessments on muscle
mass, IRS1, MAFbx, IL6, IL10, IL15, AMPK, PGC1α, HIF1α,
and LDH activity, the constraint of sample size might be
a limitation in the present study. Furthermore, additional
research is warranted to further investigate the toxic effects
of DOX on skeletal muscle in a tumor diabetic animal
model.
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